Ironwood Pharmaceuticals

#8608

Rank

$183.55M

Marketcap

United States

Country

Leadership team

Ms. Julie H. McHugh (Exec. Chairman)

Mr. Thomas A. McCourt (CEO & Director)

Mr. Sravan Kumar Emany (Sr. VP, Principal Financial Officer & CFO)

Products/ Services

Biotechnology, Health Care, Pharmaceutical

Number of Employees

100 - 500

Headquarters

Cambridge, Massachusetts, United States

Established

1998

Company Registration

SEC CIK number: 0001446847

Net Income

100M - 500M

Revenue

100M - 500M

Traded as

IRWD

Social Media

URL

https://www.ironwoodpharma.com

Overview

Location

Recognition and Award

References

Summary

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

History

Ironwood was established in 1998 as Camitros Corporation, and the name was changed to Ironwood Pharmaceuticals in 2003. The company's first product was sold in the U.S. in 2012 as Linzess (linaclotide), a treatment for adults with irritable bowel syndrome with constipation and adults with chronic idiopathic constipation. Linzess was the first product in the U.S. to be approved for both conditions. They currently offer five different approved products: Linzess, Trulance (plecanatide), Movantik (naloxegol), Byfavo (avaolicioconolyl tosilate) and SoluMatrix (buprenorphine).

Mission

We believe we have what it takes to achieve our vision and we're all in. Together, we're paving a path to long-term success.

Vision

Ironwood Pharmaceuticals vision is to be the premier specialty and generics biopharmaceutical company committed to improving the lives of patients through innovative therapies.

Key Team

Mr. Jason Rickard (Sr. VP & COO)

Ms. Beth Calitri (Head of Corp. Communications & Media Relations)

Mr. Mike Nanfito (VP of Sales & Sales Excellence)

Mr. John Minardo (Sr. VP, Chief Legal Officer & Sec.)

Dr. Michael Shetzline M.D., Ph.D. (Chief Medical Officer, Sr. VP and Head of Research & Drug Devel.)

Mr. Ronald Silver (Corp. Controller & Principal Accounting Officer)

Mr. Marcel Moulaison (VP of Technical Operations)

Recognition and Awards

Ironwood Pharmaceuticals has been the recipient of numerous awards since its founding in 1998. These awards include the Ernst & Young Entrepreneur of the Year, the Biotechnology Industry Organization Partnering for Global Health award, and the Matrix Award for Corporate Social Responsibility.